Treating advanced esophageal cancer with dalpiciclib and pyrotinib
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two targeted drugs (dalpiciclib and pyrotinib) for people with advanced esophageal squamous cell carcinoma whose cancer has gotten worse during or after first chemotherapy. The goal is to see if this drug pair can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with esophageal squamous cell carcinoma that has spread or come back.
- You have already tried one line of chemotherapy and it either stopped working or caused side effects you couldn't handle.
- You are able to swallow pills.
- You are willing to provide a tumor tissue sample for testing.
- You have good organ function (kidneys, liver, bone marrow) and are in generally good health aside from the cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment approach for advanced esophageal cancer that has stopped responding to immunotherapy. It aims to find better options for people whose cancer has progressed after standard treatments.
This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.
This trial is testing different treatment combinations before surgery for people with locally advanced esophageal squamous cell carcinoma. The goal is to find which approach works best based on specific biomarkers like PD-L1 levels.
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
This trial tests a combination of a new drug (SYS6010), an immunotherapy called enlonstobart, and standard chemotherapy as the first treatment for esophageal squamous cell carcinoma that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial combines a targeted immunotherapy drug (ivonescimab) with a short course of radiation to treat advanced esophageal cancer that has worsened after first treatment. It aims to see if this combination can help when standard options have stopped working.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.